Peers of CRISPR Therapeutics AG (CRSP)
Side-by-side comparison
Health Care · Biotechnology
Share price divided by TTM earnings per weighted-average shares. Shows how many dollars investors pay for each $1 of yearly profit.
Latest P/E Ratio
-10.72x
As of Oct 22, 2026
Beyond P/E Ratio, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.
| Date | P/E Ratio |
|---|---|
| Oct 22, 2026 | -10.72x |
| Oct 21, 2026 | -10.82x |
| Oct 20, 2026 | -10.69x |
| Oct 19, 2026 | -10.72x |
| Oct 16, 2026 | -10.55x |
| Oct 15, 2026 | -11.04x |
| Oct 14, 2026 | -10.76x |
| Oct 13, 2026 | -10.73x |
P/E Ratio = Current Stock Price ÷ Trailing 12-Month (TTM) Diluted EPS (or Market Cap ÷ TTM Net Income). Chartloom divides stock price by trailing twelve-month EPS, calculated by dividing TTM net income by the weighted-average share count from filings. Note: Variations in share-count conventions across data providers may cause slight differences in reported P/E multiples.
Trailing P/E is based on reported GAAP results and is one of the most widely used valuation metrics.
Read the general P/E Ratio definition, formula, and analyst usage guide.
P/E Ratio guideInformational research only; not personalized advice. Values reflect the latest available data on Chartloom and may differ from other sources.
Side-by-side comparison